Bosutinib for Chronic-Phase CML After Failure of Imatinib and Dasatinib and/or Nilotinib: 24-Month Minimum Follow-Up Update


Bosutinib for Chronic-Phase CML After Failure of Imatinib and Dasatinib and/or Nilotinib: 24-Month Minimum Follow-Up Update
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Moshe Talpaz, MD (2/20/13)

Khoury HJ et al. Bosutinib as therapy for chronic phase chronic myeloid leukemia following failure with imatinib plus dasatinib and/or nilotinib: 24-month minimum follow-up update. Proc ASH 2012;Abstract 3785.

Dr Talpaz is Alexander J Trotman Professor of Leukemia Research, Associate Director of Translational Research at UM Comprehensive Cancer Center, Associate Chief of the Division of Hematology/Oncology and Director of Hematologic Malignancies at the University of Michigan Medical Center in Ann Arbor, Michigan.